An article by Drummond et al. (2023) The article examines how health technology assessment bodies are tackling the challenge of assessing the value of cell and gene therapies (also known as advanced therapy medicinal products (ATMPs) in Europe). To do so, the authors:
…conducted i) a targeted literature review on the clinical and economic evidence needs for these therapies, and ii) an in-depth analysis of HTA reports from 8 major jurisdictions for 9 cell and gene therapies across 10 indications, along with all associated publicly available documents on managed entry agreements and post-launch evidence requirements.
The authors used a data extraction form of Drummond et al. (2019).
The authors examine these elements and determine the proportion of which were cited positively, negatively, or neutrally.
It is also interesting that while some broader or societal elements of value were cited in the ATMP value assessment, this was far from omnipresent.
The article is interesting throughout and you can read it in full. here.
